CD19 and neoplasm: CAR-induced host immunity, including antitumor responses of endogenous T cells, activation of NK cells, and polarization of TAMs towards a M1 phenotype, was found in multiple CAR T cell platforms, such as CD19-, IL13Rα2-, VEGFR-, and mesothelin-targeted CARs using implantable syngeneic tumor models [126,133,134,135].